Advances in Cancer Immunotherapy™: A Focus on Monoclonal Antibodies and Antibody-drug Conjugates

When:  Sep 20, 2023 from 12:00 to 16:00 (PT)
This program will be hybrid. Please attend in-person or virtually!


Alexandra Drakaki, MD, PhD - University of California, Los Angeles
Sara Hurvitz, MD - University of California, Los Angeles
Monica D. Mead, MD - David Geffen School of Medicine at UCLA

Program Purpose

Specifically designed by the Society for Immunotherapy of Cancer (SITC) for practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals, the Advances in Cancer Immunotherapy™ (ACI) programs are introductory, CME-, CPE-, CNE-, MOC-certified programs. Presented by leading authorities in tumor immunology and cancer immunotherapy, at the conclusion of this activity, participants of this should be able to:

  • Describe the mechanisms of monoclonal antibodies and antibody-drug conjugates.
  • Summarize recent updates in the use of monoclonal antibodies and antibody-drug conjugates clinically.
  • Outline common toxicities with monoclonal antibodies and antibody-drug conjugates and their management.
Attendees will also have an opportunity for connecting with experts in the immunotherapy field at the live event, through four quarterly webinars, and indefinitely through a dedicated online community forum. These connections will serve as ongoing resources while clinical oncologists and other healthcare providers incorporate immunotherapy into practice.

For more information on the program, click below.


View the SITC Meeting Code of Conduct.


Sheraton Gateway Los Angeles
6101 West Century Blvd
Los Angeles, CA 90045